Hanmi Pharm

128940 · KOSPI · ₩128940 · 한미약품

₩369,500▲ ₩19,000 (5.42%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩258,519

vs the current price (₩369,500)

Enterprise value
₩3.3T
Equity value
₩3.3T
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩167,431
−54.7%
Base
₩258,519
−30.0%
Bull
₩410,552
+11.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Start from

Preliminary results are the company's early announcement of a quarter's sales and operating profit, before the full report. Including them swaps that quarter in for the same quarter a year earlier.

Margin path

Every year uses the cycle-average margin (14.4%).

Revenue growth

  • 5.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5.1% a year, annual reports), fading to 3% by year 5.

  • 4.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5.1% a year, annual reports), fading to 3% by year 5.

  • 4.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5.1% a year, annual reports), fading to 3% by year 5.

  • 3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5.1% a year, annual reports), fading to 3% by year 5.

Business

  • 14.4%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 5.7%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 4%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 27.3%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.39, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩1.7T
Net debt (borrowings and leases − cash and deposits)
−₩137B
+ Stakes and investments
₩17B
Associates, long-term financial assets and deposits (book value)
− Minority interests
₩185B
Shares
12,810,991
Share price
₩369,500
Market cap
₩4.7T

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩1.5T₩1.5T₩1.5T₩1.7T₩1.8T₩1.9T₩2T₩2T
Growth12.0%0.3%3.5%5.1%4.6%4.1%3.5%3.0%
EBIT₩221B₩216B₩258B₩251B₩262B₩273B₩282B₩291B
EBIT margin14.8%14.5%16.7%14.4%14.4%14.4%14.4%14.4%
After-tax EBIT₩160B₩157B₩187B₩182B₩190B₩198B₩205B₩211B
+ Depreciation₩86B₩86B₩86B₩99B₩104B₩108B₩112B₩115B
− Capital spending₩44B₩63B₩77B₩70B₩73B₩76B₩78B₩81B
− Working capital₩133B−₩179B₩240B₩23B₩22B₩20B₩18B₩16B
Free cash flow₩70B₩359B−₩44B₩188B₩199B₩210B₩220B₩229B
Discount factor———0.9310.8670.8080.7520.700
Present value———₩175B₩173B₩169B₩165B₩160B

Terminal value ₩3.6T, worth ₩2.5T today: 75% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩109,580 a share)Now 3.37×₩360,1523.29×₩450,2214.11×₩531,4714.85×
Price / earnings (last 12 months: ₩16,942 a share)Now 21.8×₩371,40121.9×₩596,53235.2×₩887,28052.4×
P/E on run-rate earnings (preliminary Q3 2026 × 4: ₩3,820 a share)Now 96.7×₩83,73821.9×₩134,49735.2×₩200,05152.4×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩273,642₩292,847₩316,400₩345,980₩384,263
6.9%₩250,565₩265,973₩284,507₩307,236₩335,781
7.4%₩231,091₩243,652₩258,519₩276,401₩298,330
7.9%₩214,435₩224,812₩236,929₩251,271₩268,520
8.4%₩200,024₩208,697₩218,706₩230,392₩244,224

Now (TTM)

Market cap
₩4.7T
Enterprise value
₩4.6T
P/E
21.8×
P/B
3.4×
P/S
2.9×
EV/EBITDA
11.2×
Dividend yield
0.5%

Over time (at each year end)

20252024202320222021
Price₩452,000₩280,500₩352,500₩298,000₩276,000
Market cap₩5.8T₩3.6T₩4.5T₩3.8T₩3.5T
P/E34.2×29.6×30.9×46.1×52.8×
P/B4.6×3.3×4.7×4.4×4.4×
P/S3.7×2.4×3.0×2.9×2.9×
EV/EBITDA17.8×12.9×16.4×17.9×19.7×
Dividend yield0.4%0.4%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Hanmi Pharm21.8×3.4×2.9×11.2×0.5%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940

Source: KRX statistical information